Literature DB >> 17082236

Enhanced aldosterone signaling in the early nephropathy of rats with metabolic syndrome: possible contribution of fat-derived factors.

Miki Nagase1, Shigetaka Yoshida, Shigeru Shibata, Takashi Nagase, Takanari Gotoda, Katsuyuki Ando, Toshiro Fujita.   

Abstract

Metabolic syndrome is an important risk factor for proteinuria and chronic kidney disease independent of diabetes and hypertension; however, the underlying mechanisms have not been elucidated. Aldosterone is implicated in target organ injury of obesity-related disorders. This study investigated the role of aldosterone in the early nephropathy of 17-wk-old SHR/NDmcr-cp, a rat model of metabolic syndrome. Proteinuria was prominent in SHR/NDmcr-cp compared with nonobese SHR, which was accompanied by podocyte injury as evidenced by foot process effacement, induction of desmin and attenuation of nephrin. Serum aldosterone level, renal and glomerular expressions of aldosterone effector kinase Sgk1, and oxidative stress markers all were elevated in SHR/NDmcr-cp. Mineralocorticoid receptors were expressed in glomerular podocytes. Eplerenone, a selective aldosterone blocker, effectively improved podocyte damage, proteinuria, Sgk1, and oxidant stress. An antioxidant tempol also alleviated podocyte impairment and proteinuria, along with inhibition of Sgk1. As for the mechanisms of aldosterone excess, visceral adipocytes that were isolated from SHR/NDmcr-cp secreted substances that stimulate aldosterone production in adrenocortical cells. The aldosterone-releasing activity of adipocytes was not inhibited by candesartan. Adipocytes from nonobese SHR did not show such activity. In conclusion, SHR/NDmcr-cp exhibit enhanced aldosterone signaling, podocyte injury, and proteinuria, which are ameliorated by eplerenone or tempol. The data also suggest that adipocyte-derived factors other than angiotensin II might contribute to the aldosterone excess of this model.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17082236     DOI: 10.1681/ASN.2006080944

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  89 in total

Review 1.  Activation of the aldosterone/mineralocorticoid receptor system in chronic kidney disease and metabolic syndrome.

Authors:  Miki Nagase
Journal:  Clin Exp Nephrol       Date:  2010-06-09       Impact factor: 2.801

Review 2.  The role of aldosterone in the metabolic syndrome.

Authors:  Marie Briet; Ernesto L Schiffrin
Journal:  Curr Hypertens Rep       Date:  2011-04       Impact factor: 5.369

3.  Mitochondrial dysfunction mediates aldosterone-induced podocyte damage: a therapeutic target of PPARγ.

Authors:  Chunhua Zhu; Songming Huang; Yanggang Yuan; Guixia Ding; Ronghua Chen; Bicheng Liu; Tianxin Yang; Aihua Zhang
Journal:  Am J Pathol       Date:  2011-05       Impact factor: 4.307

4.  Protection of podocytes from hyperhomocysteinemia-induced injury by deletion of the gp91phox gene.

Authors:  Chun Zhang; Jun-Jun Hu; Min Xia; Krishna M Boini; Christopher A Brimson; Laura A Laperle; Pin-Lan Li
Journal:  Free Radic Biol Med       Date:  2010-01-29       Impact factor: 7.376

5.  Disparate effects of eplerenone, amlodipine and telmisartan on podocyte injury in aldosterone-infused rats.

Authors:  Wei Liang; Cheng Chen; Jing Shi; Zhilong Ren; Fengqi Hu; Harry van Goor; Pravin C Singhal; Guohua Ding
Journal:  Nephrol Dial Transplant       Date:  2010-08-20       Impact factor: 5.992

6.  Diverse diuretics regimens differentially enhance the antialbuminuric effect of renin-angiotensin blockers in patients with chronic kidney disease.

Authors:  Enrique Morales; Jara Caro; Eduardo Gutierrez; Angel Sevillano; Pilar Auñón; Cristina Fernandez; Manuel Praga
Journal:  Kidney Int       Date:  2015-08-26       Impact factor: 10.612

Review 7.  Aldosterone Production and Signaling Dysregulation in Obesity.

Authors:  Andrea Vecchiola; Carlos F Lagos; Cristian A Carvajal; Rene Baudrand; Carlos E Fardella
Journal:  Curr Hypertens Rep       Date:  2016-03       Impact factor: 5.369

Review 8.  Kidney and epigenetic mechanisms of salt-sensitive hypertension.

Authors:  Wakako Kawarazaki; Toshiro Fujita
Journal:  Nat Rev Nephrol       Date:  2021-02-24       Impact factor: 28.314

9.  Body Mass Index Predicts 24-Hour Urinary Aldosterone Levels in Patients With Resistant Hypertension.

Authors:  Tanja Dudenbostel; Lama Ghazi; Mingchun Liu; Peng Li; Suzanne Oparil; David A Calhoun
Journal:  Hypertension       Date:  2016-08-15       Impact factor: 10.190

Review 10.  Interaction of aldosterone and extracellular volume in the pathogenesis of obesity-associated kidney disease: a narrative review.

Authors:  Andrew S Bomback; Philip J Klemmer
Journal:  Am J Nephrol       Date:  2009-03-20       Impact factor: 3.754

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.